ロード中...
Therapeutic Potential of JAK2 Inhibitors for the Management of Myelofibrosis
Myelofibrosis (either primary or post-polycythemia vera/essential thrombocythemia) is a chronic and debilitating myeloproliferative neoplasm for which there is no well-accepted standard of care. Clinical manifestations of this disease (eg, cytopenias, splenomegaly, bone marrow fibrosis) and constitu...
保存先:
| 出版年: | Clin Cancer Res |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5017533/ https://ncbi.nlm.nih.gov/pubmed/20215535 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-2836 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|